Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 6
2000 7
2001 16
2002 12
2003 25
2004 18
2005 14
2006 10
2007 10
2008 11
2009 17
2010 23
2011 27
2012 25
2013 34
2014 23
2015 21
2016 10
2017 15
2018 17
2019 15
2020 6
2021 6
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
We enrolled HIV-1 infected adults (aged 18 years) who were previously untreated (HIV-1 RNA 500 copies per mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir …
We enrolled HIV-1 infected adults (aged 18 years) who were previously untreated (HIV-1 RNA 500 copies per mL); HLA-B*5701-nega …
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Orkin C, et al. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130806 Clinical Trial.
BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously receiv …
BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infect …
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
Jesson J, Dahourou DL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet HIV. 2016 Feb;3(2):e64-75. doi: 10.1016/S2352-3018(15)00225-8. Epub 2015 Dec 7. Lancet HIV. 2016. PMID: 26847228 Review.
All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. ...In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1.08; 95% CI 0.19-6.15), …
All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. ...In th …
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Shey MS, et al. Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Cochrane Database Syst Rev. 2013. PMID: 23543540 Free PMC article. Review.
OBJECTIVES: To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. ...Using the GRADE approach, we rated the overall quality of the evidence on the relative effects …
OBJECTIVES: To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for i …
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications.
Tikiso T, McIlleron H, Burger D, Gibb D, Rabie H, Lee J, Lallemant M, Cotton MF, Archary M, Hennig S, Denti P. Tikiso T, et al. Br J Clin Pharmacol. 2022 Feb;88(2):403-415. doi: 10.1111/bcp.14984. Epub 2021 Aug 12. Br J Clin Pharmacol. 2022. PMID: 34260082 Free PMC article.
AIMS: Abacavir is part of WHO-recommended regimens to treat HIV in children under 15 years of age. ...During coadministration of rifampicin-based antituberculosis treatment and super-boosted lopinavir in a 1:1 ratio with ritonavir, abacavir exposure decreased …
AIMS: Abacavir is part of WHO-recommended regimens to treat HIV in children under 15 years of age. ...During coadministration …
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Here, we report the week-144 secondary outcome of proportion of participants with plasma HIV-1 RNA less than 50 copies per mL at week 144, by US Food and Drug Administration Snapshot algorithm, analysed in the same manner. ...At week 144, bictegravir, emtricitabine, and te …
Here, we report the week-144 secondary outcome of proportion of participants with plasma HIV-1 RNA less than 50 copies per mL at week …
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. Shey M, et al. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481. doi: 10.1002/14651858.CD005481.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588374 Updated. Review.
BACKGROUND: The human immunodeficiency virus (HIV) has become one of the greatest challenges to global public health. ...OBJECTIVES: The aim of this review was to evaluate the effects of Trizivir, a fixed-dose combination of three NRTIs (abacavir-lamivudine-zidovudi …
BACKGROUND: The human immunodeficiency virus (HIV) has become one of the greatest challenges to global public health. ...OBJECTIVES: …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Orkin C, et al. Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4. Lancet HIV. 2021. PMID: 33794181 Clinical Trial.
BACKGROUND: There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden, drug-food interactions, and adherence. The phase 3 ATLAS and FLAIR …
BACKGROUND: There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV tr …
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark.
Pedersen KBH, Knudsen A, Møller S, Siebner HR, Hove JD, Gerstoft J, Benfield T. Pedersen KBH, et al. BMJ Open. 2023 Aug 21;13(8):e075673. doi: 10.1136/bmjopen-2023-075673. BMJ Open. 2023. PMID: 37604629 Free PMC article. Clinical Trial.
Abacavir has been associated with an increased risk of myocardial infarction, but the mechanism is unknown. Additionally, abacavir may be obesogenic which could mediate an additional risk factor of CVD. ...
Abacavir has been associated with an increased risk of myocardial infarction, but the mechanism is unknown. Additionally, abacavir …
Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.
Jesson J, Saint-Lary L, Revegue MHDT, O'Rourke J, Townsend CL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet Child Adolesc Health. 2022 Oct;6(10):692-704. doi: 10.1016/S2352-4642(22)00213-9. Epub 2022 Sep 2. Lancet Child Adolesc Health. 2022. PMID: 36058225 Free PMC article.
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. We assessed the safety and efficacy profile of abacavir used in first, second, or subsequent lines of treatment for infants, children, and adolescents liv …
BACKGROUND: Abacavir is a nucleoside reverse transcriptase inhibitor recommended in paediatric HIV care. We assessed the safet …
343 results